[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650665":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":34,"centralContacts":34,"locations":40,"responsibleParty":60,"collaborators":34,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":34,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":34,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":43,"whyStopped":34,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Minia University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"PPI group","EXPERIMENTAL","Participants receive PPI therapy in addition to vitamin D supplementation and feeding instructions.",[13,14,15],"Drug: PPI","Dietary Supplement: vitamin D","Behavioral: feeding instruction",{"label":17,"type":18,"description":19,"interventionNames":20},"standard group","ACTIVE_COMPARATOR","Participants receive vitamin D supplementation and feeding instructions only.",[14,15],[22,29,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","PPI","Proton pump inhibitor therapy administered according to the study protocol",[9],[28],"Esomeprazole",{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DIETARY_SUPPLEMENT","vitamin D","Vitamin D supplementation administered according to the study protocol.",[9,17],null,{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":34},"BEHAVIORAL","feeding instruction","Standard feeding instructions provided to caregivers according to the study protocol.",[9,17],[41],{"facility":42,"status":43,"city":44,"state":45,"zip":34,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"faculty of Medicine, Minia University","RECRUITING","Minya","Minya Governorate","Egypt","EG",{"type":49,"coordinates":50},"Point",[51,52],30.75813,28.09193,{"lat":52,"lon":51},[55],{"name":56,"role":57,"phone":58,"phoneExt":34,"email":59},"Al shimaa Abd el monem, MD","CONTACT","01033487196","alshima.dakhly@mu.edu.eg",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Al shimaa Abd el monem","Assistant lecturer","100650665","assessing-the-role-of-proton-pump-inhibitors-in-reducing-aspiration-incidence-in-pediatric-laryngomalacia-cases-100650665",false,"NCT07750379","Assessing the Role of Proton Pump Inhibitors in Reducing Aspiration Incidence in Pediatric Laryngomalacia Cases","Inclusion Criteria:\n\n1. Children diagnosed with laryngomalacia by laryngoscopic examination with a history of recurrent choking attacks or aspiration symptoms.\n2. Children aged from 6 months to 5 years.\n\nExclusion Criteria:\n\n1. Children with any neurological impairment.\n2. Children with other congenital anomalies.\n3. Children with other causes of respiratory distress","ALL","6 Months","5 Years",{"count":74,"type":75},60,"ESTIMATED","INTERVENTIONAL",[78],"NA","Laryngomalacia is the most common congenital laryngeal anomaly in children and is frequently associated with aspiration. This randomized controlled study aims to assess the role of proton pump inhibitor (PPI) therapy in reducing the incidence of aspiration in pediatric patients with laryngomalacia. Eligible participants will be randomly assigned to either a PPI treatment group or a control group. Clinical and swallowing assessments will be performed to compare aspiration incidence and swallowing outcomes between the two groups",[81],"Laryngomalacia",[83,84,24,85,86],"laryngomalacia","aspiration","GERD","Pediatric","2026-08-02",{"date":89,"type":90},"2026-08-06","ACTUAL",{"date":92,"type":90},"2026-04-28",{"date":94,"type":75},"2026-12-31",{"name":5,"class":6},1]